BONFANTI, PAOLO
 Distribuzione geografica
Continente #
NA - Nord America 10.927
EU - Europa 8.836
AS - Asia 4.957
SA - Sud America 486
AF - Africa 64
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 3
Totale 25.285
Nazione #
US - Stati Uniti d'America 10.742
SG - Singapore 2.632
IT - Italia 2.274
RU - Federazione Russa 2.044
DE - Germania 1.462
SE - Svezia 969
HK - Hong Kong 965
IE - Irlanda 942
CN - Cina 488
BR - Brasile 414
ID - Indonesia 374
GB - Regno Unito 247
AT - Austria 162
VN - Vietnam 150
FI - Finlandia 141
NL - Olanda 130
UA - Ucraina 124
CA - Canada 123
IN - India 111
FR - Francia 107
TR - Turchia 61
RO - Romania 49
MX - Messico 48
ES - Italia 27
PH - Filippine 27
CZ - Repubblica Ceca 24
JP - Giappone 23
BE - Belgio 22
CO - Colombia 21
ZA - Sudafrica 18
PK - Pakistan 17
IR - Iran 16
PL - Polonia 15
AR - Argentina 14
GR - Grecia 14
CL - Cile 13
CH - Svizzera 12
DK - Danimarca 11
KE - Kenya 10
LT - Lituania 10
BG - Bulgaria 9
KR - Corea 9
PE - Perù 8
BD - Bangladesh 7
TH - Thailandia 7
AL - Albania 6
AU - Australia 6
IQ - Iraq 6
JO - Giordania 6
MY - Malesia 6
NZ - Nuova Zelanda 6
EC - Ecuador 5
IL - Israele 5
KZ - Kazakistan 5
MA - Marocco 5
PT - Portogallo 5
SA - Arabia Saudita 5
SC - Seychelles 5
SK - Slovacchia (Repubblica Slovacca) 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
EG - Egitto 4
HR - Croazia 4
NO - Norvegia 4
NP - Nepal 4
PY - Paraguay 4
UG - Uganda 4
UY - Uruguay 4
BY - Bielorussia 3
EE - Estonia 3
GH - Ghana 3
JM - Giamaica 3
KG - Kirghizistan 3
MU - Mauritius 3
OM - Oman 3
PA - Panama 3
UZ - Uzbekistan 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CR - Costa Rica 2
ET - Etiopia 2
GE - Georgia 2
HU - Ungheria 2
LB - Libano 2
LU - Lussemburgo 2
LV - Lettonia 2
MM - Myanmar 2
NG - Nigeria 2
PR - Porto Rico 2
SN - Senegal 2
TN - Tunisia 2
A1 - Anonimo 1
AO - Angola 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BW - Botswana 1
CM - Camerun 1
DO - Repubblica Dominicana 1
EU - Europa 1
Totale 25.271
Città #
Ann Arbor 2.463
Singapore 1.661
Frankfurt am Main 1.162
Hong Kong 961
Dublin 914
Fairfield 781
Chandler 748
New York 594
Santa Clara 569
Milan 549
Ashburn 479
Wilmington 409
Woodbridge 403
Princeton 385
Jakarta 366
Houston 359
Seattle 301
Cambridge 223
Moscow 219
Altamura 206
Lawrence 179
San Diego 114
Dong Ket 109
Nuremberg 108
Hefei 97
London 93
Vienna 93
Shanghai 90
Rome 83
Jacksonville 77
Helsinki 68
Chicago 67
Andover 61
Guangzhou 59
Dearborn 54
Los Angeles 53
Boardman 48
Falls Church 44
Pune 44
Galati 43
Toronto 43
Monza 38
Fremont 36
Lappeenranta 36
Council Bluffs 34
Beijing 33
Munich 31
Nanjing 31
São Paulo 30
Florence 27
Norwalk 24
Lissone 23
Ottawa 21
Turin 21
Brussels 20
Naples 20
The Dalles 20
Turku 20
Rio de Janeiro 19
Washington 19
Bogotá 17
Brno 17
Cuauhtémoc 17
Palermo 17
Brescia 16
Belo Horizonte 15
Lachine 15
Shenzhen 15
Istanbul 14
San Francisco 14
Amsterdam 13
Dallas 13
Hangzhou 13
Padova 13
Redmond 13
Bologna 12
Carate Brianza 12
Genoa 12
Jinan 12
Mexico City 12
Pisa 12
Busto Arsizio 11
Groningen 11
Hyderabad 11
Seregno 11
Tokyo 11
Athens 10
Bari 10
Bexley 10
Brooklyn 10
Kilburn 10
Kocaeli 10
Kolkata 10
Manila 10
Paris 10
Romola 10
Acquafredda 9
Atlanta 9
Huizen 9
Nairobi 9
Totale 16.367
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 435
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study 378
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 260
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 250
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 247
A second update on mapping the human genetic architecture of COVID-19 225
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 224
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 214
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 214
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 214
An immune-based biomarker signature is associated with mortality in COVID-19 patients 206
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 205
Mapping the human genetic architecture of COVID-19 203
Delirium in Patients with SARS‐CoV‐2 Infection: A Multicenter Study 202
Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare 199
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 196
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 196
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 194
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 193
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 192
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 189
High rates of 30-day mortality in patients with cirrhosis and COVID-19 186
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 183
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study 183
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 180
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 177
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 174
Alternative pre-analytical strategies for SARS CoV 2 RNA detection 174
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 173
Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment? 170
Hospital-Acquired Infections in Critically Ill Patients With COVID-19 169
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 163
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) 162
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 162
RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies 160
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 159
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 159
HIV and metabolic syndrome - A comparison with the general population 149
The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: A randomized multicentric study 149
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 148
Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study 145
Association Between Sex Hormone Levels and Clinical Outcomes in Patients With COVID-19 Admitted to Hospital: An Observational, Retrospective, Cohort Study 145
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 144
Two-year cardio-pulmonary follow-up after severe COVID-19: a prospective study 143
The effect of frailty on in-hospital and medium-term mortality of patients with COronaVIrus Disease-19: the FRACOVID study 141
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 140
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 139
Assessing the mortality risk in older patients hospitalized with a diagnosis of sepsis: the role of frailty and acute organ dysfunction 138
Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection 137
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 134
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 133
Streptococcus agalactiae infective endocarditis complicated by multiple mycotic hepatic aneurysms and massive splenic infarction: A case report 129
A multidisciplinary approach to screen the post-COVID-19 conditions 127
Beware of biases in observational studies on anti-spike monoclonal antibodies 127
Frailty index predicts poor outcome in COVID-19 patients 125
Atrial Fibrillation Incidence in SARS-COV-2 Infected Patients: Predictors and Relationship with in-Hospital Mortality 124
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering 124
Being a Doctor Will Never Be the Same After the COVID-19 Pandemic 123
Pillars of long-term antiretroviral therapy success 121
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 121
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 121
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 121
Steroids in severe COVID-19 patients: A retrospective analysis on the first pandemics in Lombardy 120
Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients 118
Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible from the STOPSHIV Project Cohort 117
Weight gain: A possible side effect of all antiretrovirals 116
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 114
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study 111
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 109
Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study 108
Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti? 108
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: Results from a large observational cohort study (SCOLTA) 107
Ruolo delle strutture ambulatoriali extra-ospedaliere per pazienti con COVID-19: l’esperienza dell’Hotspot COVID di Monza. Role of outpatient facilities for patients with COVID-19: the experience of the COVID Hotspot in Monza. 106
Safety and tolerability of Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 106
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 104
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project 104
Factors Associated With Weight Gain in People Treated With Dolutegravir 104
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study 104
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 103
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing? 103
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 102
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 102
Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19 102
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view 100
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients 100
PRESENTAZIONE DEL VADEMECUM DI SIMIT-LOMBARDIA, PER LE VACCINAZIONI DELL’ADULTO A RISCHIO PER CONDIZIONE O PATOLOGIA 99
Factors associated with hospital admission for COVID-19 in HIV patients 99
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation 99
Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: A multicentric case-control study 97
Compassionate Use of Remdesivir in Children With Severe COVID-19 95
Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort 94
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 93
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 93
Atrial fibrillation and clinical outcomes in a cohort of hospitalized patients with sars-cov-2 infection and chronic kidney disease 92
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 92
Insights on HIV infection, some reflecting after eight years of the Journal. 90
One-year survival and Quality of Life of first wave COVID-19 invasively ventilated patients in Lombardy, Italy 89
New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: A budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy) 89
Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir 88
Frailty and long-COVID: is COVID-19 responsible for a transition in frailty status among older adults who survived hospitalization for COVID-19? 87
Totale 14.782
Categoria #
all - tutte 127.360
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.360


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020237 0 0 0 0 0 0 0 0 0 0 101 136
2020/20213.854 91 158 232 319 314 410 248 385 518 394 329 456
2021/20222.857 306 319 311 238 160 207 117 201 169 124 194 511
2022/20234.492 587 1.070 440 387 359 707 98 236 290 71 136 111
2023/20243.837 150 117 223 136 475 923 622 127 358 147 80 479
2024/20259.864 646 1.407 679 529 847 706 757 331 1.009 1.747 1.206 0
Totale 26.312